Supplemental Material Table 1: Patient characteristics of incident cases of IPAH included (n = 129) and excluded (n = 55) from MCID estimation

|                          | n     | Discovery cohort | n     | Excluded patients |
|--------------------------|-------|-----------------|-------|-------------------|
| Age, years               | 129   | 54.4 (16.4)     | 55    | 57.3 (27.7)       |
| Sex, female %            | 129   | 63.9            | 55    | 70.9              |
| RAP, mmHg                | 109   | 10.8 (13.4)     | 40    | 10.2 (5.1)        |
| Mean PAP, mmHg           | 109   | 51.5 (11.6)     | 40    | 51.4 (11.5)       |
| PVR, dynes               | 109   | 1304 (1030)     | 39    | 1214 (702)        |
| CO, l/min                | 109   | 3.6 (1.1)       | 39    | 3.9 (1.9)         |
| CAMPHOR score            |       |                 |       |                   |
| Symptoms                 | 129   | 12 (7)          | 42    | 13 (7)            |
| Activity                 | 129   | 12 (7)          | 42    | 12 (8)            |
| Quality of Life          | 129   | 10 (7)          | 42    | 12 (7)            |
| 6MWD, metres             | 110   | 291 (123)       | 33    | 274 (126)         |

Values expressed as mean (standard deviation). Patients excluded from MCID estimation due to the absence of CAMPHOR scale scores available for comparison at treatment-naïve baseline and post-PAH treatment.

IPAH: Idiopathic pulmonary arterial hypertension; MCID: Minimal Clinically Important Difference; CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review Questionnaire.
**Supplemental Material Table 2**: CAMPHOR subscale scores for global rating of health status (n = 129)

|        | n  | Symptoms | Activity | Quality of Life |
|--------|----|----------|----------|-----------------|
| Poor   | 39 | 17 (5)   | 18 (6)   | 16 (5)          |
| Fair   | 81 | 14 (5)   | 14 (6)   | 12 (6)          |
| Good   | 81 | 7 (5)    | 7 (5)    | 5 (5)           |
| Very Good | 21 | 2 (2)    | 3 (2)    | 2 (2)           |

Values expressed as mean (standard deviation). Each individual provided global health ratings at treatment-naïve baseline and post PAH treatment. Total missing observations n = 36.

CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review